Genpact Limited: Q1 2014 Form 10-Q Summary
Business context and reporting period
Genpact is a global provider of business-process management, information technology, analytics and related operational services. The company reported approximately 64,000 employees in 24 countries and more than 100 Fortune Global 500 clients. This unaudited Form 10-Q covers the three months ended March 31, 2014, compared primarily with the three months ended March 31, 2013.
Key financial metrics
| Metric | Q1 2014 | Q1 2013 | Change |
|---|---|---|---|
| Total revenue | $528.2 million | $503.8 million | 4.8% increase |
| Global Client revenue | $418.0 million | $386.8 million | 8.1% increase |
| GE revenue | $110.2 million | $117.0 million | 5.9% decrease |
| Gross profit | $203.9 million | $192.1 million | 6.1% increase |
| Gross margin | 38.6% | 38.1% | 50 basis-point increase |
| Operating income | $77.2 million | $73.9 million | 4.5% increase |
| Operating margin | 14.6% | 14.7% | 10 basis-point decrease |
| Net income | $50.9 million | $48.3 million | 5.4% increase |
| Net income attributable to shareholders | $50.6 million | $46.7 million | 8.3% increase |
| Diluted EPS | $0.21 | $0.20 | Increase |
| Cash flow from operations | $14.2 million | $31.5 million | 54.9% decrease |
Revenue growth was led by business-process management revenue of $398.0 million, up 3.7%, and information technology revenue of $130.2 million, up 8.6%. IT services increased to 24.7% of revenue from 23.8%. Annualized revenue per employee declined to $33,800 from $34,500, while average headcount increased to approximately 62,400 from 58,900.
Cash and cash equivalents were $567.3 million at March 31, 2014, compared with $571.3 million at December 31, 2013. Total long-term debt, excluding capital leases, was $656.8 million, including $652.5 million due after one year. The company reported compliance with applicable financial covenants. Total contractual cash obligations were $1.15 billion, including $782.3 million of long-term debt obligations and $150.2 million of operating lease obligations.
Material changes versus the prior comparable period
- Global Client revenue increased 8.1% and represented 79.1% of total revenue, up from 76.8%. GE revenue declined to 20.9% of total revenue from 23.2%.
- Gross margin improved because of higher operating efficiencies, personnel deployment and foreign-exchange effects.
- SG&A expense increased 8.2% to $122.5 million, or 23.2% of revenue, reflecting investments in sales and relationship-management teams, higher marketing and professional-services costs, travel and wage inflation.
- Operating margin declined modestly despite higher gross margin because SG&A and acquired-intangible amortization increased.
- The effective tax rate declined to 24.3% from 27.0%, primarily because of continued growth in lower-tax and tax-exempt locations, particularly India.
- Operating cash flow declined primarily because of lower client advances, non-recurring employee-related payments, higher operating and statutory payments, and changes in other operating liabilities.
- Investing cash usage improved to $14.4 million from $61.7 million because Q1 2014 included no acquisitions, compared with acquisition spending in Q1 2013.
- Financing cash flow changed to a $5.1 million use from a $43.9 million source, primarily because there were no revolving-credit borrowings in Q1 2014 and stock-plan proceeds were lower.
Guidance, outlook, commentary and unusual items
- The filing does not provide a clear quantitative full-year revenue or earnings guidance figure.
- Management stated that operating cash flow, cash reserves and debt capacity are expected to be sufficient to fund operations, growth and expansion.
- On April 8, 2014, after quarter-end, Genpact repurchased 17.3 million shares for approximately $302.6 million at $17.50 per share under a modified Dutch-auction tender offer.
- On April 23, 2014, Genpact agreed to acquire Pharmalink for cash consideration of $124.3 million, subject to customary adjustments and closing conditions, plus contingent earn-out consideration of up to $24.9 million. Closing was expected in Q2 2014.
- Earn-out remeasurement produced $1.6 million of other operating income in Q1 2014, compared with $0.1 million in Q1 2013.
- Foreign-exchange forward contracts had aggregate notional amounts of approximately $1.86 billion at March 31, 2014 and a net balance-sheet exposure liability of approximately $146.3 million. These amounts are not equivalent to cash obligations or direct market exposure.
- Key stated risks include client retention and concentration, dependence on the United States and Europe, GE-related revenue, wage inflation, employee attrition, competition, foreign-exchange volatility, interest-rate and LIBOR changes, acquisitions and integration, technology disruptions or breaches, tax changes and regulatory developments.
- Indian tax authorities issued a draft assessment in March 2014 concerning certain 2009 and 2010 transactions. Genpact estimated a potential tax claim of approximately $43 million, including interest, but stated that the assessment was not final and that it believes the transactions should not be taxable.
- No material legal proceedings were identified by management, and management concluded that disclosure controls were effective as of March 31, 2014.
Most important facts for investors to verify
- Whether Global Client growth can offset the continuing reduction in GE-related revenue.
- The sustainability of the 38.6% gross margin and whether higher SG&A investment will pressure operating margins.
- Conversion of earnings into cash, given the 54.9% year-over-year decline in operating cash flow.
- Post-quarter-end liquidity after the $302.6 million share repurchase and the planned Pharmalink acquisition.
- Debt repayment requirements, floating-rate exposure and compliance with credit-facility covenants.
- The outcome and timing of the Indian tax assessment and the potential approximately $43 million claim.
- Foreign-exchange effects, including the substantial hedging portfolio and its impact on accumulated other comprehensive income.